Promising Parkinson's data in 52-week study
AbbVie (NYSE: ABBV) has presented Phase III results evaluating the safety, tolerability and efficacy of the investigational candidate ABBV-951 (foslevodopa/foscarbidopa) in advanced Parkinson’s disease.
The US drugmaker published the abstract at the European Academy of Neurology (EAN) Congress in Vienna, showcasing 12-month results of treatment with ABBV-951, which showed improvements in motor complications as early as week one and persisting through week 52, as well as an increase in ‘on’ time without troublesome dyskinesia, and a decrease in “off” time.
The M15-741 study concluded that ABBV-951 was generally safe, improved motor complications and morning akinesia, providing a potential efficacious and minimally invasive therapeutic alternative for advanced Parkinson’s disease, that does not require surgery.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze